semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hepatocellular Carcinoma (HCC) Key Confirmed diagnosis of HCC by histological examination or by non-invasive according to European Association for the Study of the Liver (EASL) or American Association for the Study of Liver Disease (AASLD) guidelines (Part 1, 2 and 3) For Part 1 and 2, the patient has unresectable disease and has been previously treated with sorafenib, has declined treatment with sorafenib, or does not have access to sorafenib For Part 3, the patient has not received prior treatment with a TKI Child-Pugh class A with no clinically apparent ascites Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 For Part 1, willing to provide archived tumor tissue (if available) and willing to undergo pre and on-treatment tumor biopsy (if considered safe and medically feasible by the treating investigator) For Part 2 and 3, all patients must have an FGF19 IHC result available. Only FGF19 IHC+ HCC patients will be eligible for Part 3. Key  Central nervous system metastases Platelet count <75,000/mL Absolute neutrophil count <1000/mL Hemoglobin <8 g/dL Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5x the upper limit of normal (ULN) Total bilirubin >2.5 mg/dL International normalized ratio (INR) >2.3 or prothrombin time (PT) >6 seconds above control Estimated (Cockroft-Gault formula) or measured creatinine clearance <40 mL/min
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Hepatitis C Human Immunodeficiency Virus (HIV) Patients over 18 with HIV infection and active chronic hepatitis or SVR after treatment  None
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-66.0,  Hepatic and Hepatobiliary Disorders Males and females ≥18 years of age and less than 66 years old Patients with gastrointestinal symptoms (fatigue, abdominal pain/discomfort, early satiety, fullness discomfort after meal, nausea/vomiting, belching/abdominal distension, at least one rated as "Moderate Problem" or higher severity at screening visit) in acute and chronic liver diseases receiving conventional treatment for the underlying pathology Before entering the study, patients will be advised to stop alcohol intake and must agree not to consume alcohol and undergo alcohol withdrawal program, diet control, and exercise program The patient is able and willing to undertake all study required procedures and has the ability to take oral medications Patients with nonalcoholic fatty liver disease (NAFLD) diagnosed by ultrasound examination in absence of severe fibrosis as per Investigator's judgment Diagnosis of acute or chronic viral hepatitis as manifested by a combination of the following symptoms: jaundice (acute viral hepatitis), dark-colored urine (acute viral hepatitis), light-colored stools (acute viral hepatitis), pruritus, pruritic red hives, fever, nausea, vomiting, anorexia, aversion to smoking and right upper abdominal discomfort, pain or feeling of pressure, with abnormal alanine aminotransferase (ALT) (approximately 1.5 x upper limit of normal [ULN]) Patient has given written informed consent Fertile patients must agree to use an acceptable method of contraception to avoid pregnancy for the duration of the study Total abstinence from sexual intercourse (minimum one complete menstrual cycle prior to study drug administration) Vasectomized partner of female subjects  Patients <18 years of age and >66 years old Female patient of childbearing potential without negative pregnancy test Breastfeeding woman Hypersensitivity to phosphatidylcholine or any substance of the product Patient is known to be human immunodeficiency virus (HIV) positive Congenital lack of α-1 antitrypsin Gastroesophageal Reflux Disease (GERD) Autoimmune hepatitis Fulminant hepatitis Severe steatohepatitis: transaminases level is beyond 5 times upper normal range
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Chronic Delta Hepatitis Key 1. Male or female, 18 to 65 years of age, inclusive 2. Chronic HDV infection documented by a positive HDV antibody (Ab) test of at least 6 months duration and detectable HDV RNA by qPCR at study entry 3. Liver biopsy demonstrating evidence of chronic hepatitis 4. Willingness to practice appropriate contraception Key  Previous use of lonafarnib 2. Co-infected with HIV or HCV 3. Active jaundice defined by total bilirubin level >2.0 mg/dL and known not to have Gilbert's disease 4. Decompensated liver disease or cirrhosis, history of bleeding esophageal varices, ascites, or hepatic encephalopathy 5. Serum creatinine concentration ≥1.5 times upper limit of normal (ULN) 6. Evidence of another form of viral hepatitis or another form of liver disease 7. Evidence of hepatocellular carcinoma 8. Use of alpha interferon, either interferon alfa-2a or interferon alfa-2b, or pegylated interferon alfa-2a within 2 months before the start of screening 9. Concomitant use of any of the following: 1. Medications or foods that are known moderate or strong inducers or inhibitors of CYP3A4 or CYP2C19 2. Drugs known to prolong the PR or QT interval 3. Receipt of systemic immunosuppressive therapy within the 3 months before start of screening 4. Statins, due to inhibition of mevalonate synthesis, which reduces protein prenylation 5. Medications contraindicated in the prescribing information for ritonavir
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Hepatitis C Signed informed consent Ages 18-70 HCV-infected patients being treated with direct-acting antiviral (DAA) therapy  Pregnant women or females of childbearing potential that are not on contraception Institutionalized or mentally disabled persons Prisoners Unwilling or unable to provide informed consent Subjects who are HIV positive Anticipated inability to follow up Chronic anemia Platelet count < 100 for liver biopsy patients who have documented fatty liver disease by ultrasound prior to enrollment Any patient with bleeding disorders or prolonged INR Abstinent or consuming less than two drinks of alcohol per day
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Chronic Hepatitis C Infection HBV Coinfection Hepatitis B Reactivation HCV RNA positive HBsAg positive with detectable or undetectable HBV DNA Receiving pan oral direct-acting anti-HCV regimen  Pregnant or nursing female or male with pregnant female partner HIV infection Hematologic or biochemical parameters at Screening outside the protocol specified requirements Active or recent history (≤ 1 year) of drug or alcohol abuse History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hepatitis C For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com HCV RNA < 2000000 IU/mL Never taken medication for HCV No Liver Cirrhosis No advanced fibrosis Body mass index(BMI) 18-40 kg/m^2 Genotype 1-4  Infection with HCV other than GT-1, 2, 3 or GT-4 or subjects with mixed infections of any genotype Evidence of decompensated liver Subjects Infected with HIV 2 Hepatitis B virus (HBV) coinfection Liver Cirrhosis Advanced fibrosis (F3-F4)
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Hepatitis C HCV RNA Positive and Genotype 1b No history or signs or symptoms of decompensated liver disease or hepatocellular carcinoma within 6 months A patient who is on dialysis, or if not MDRD eGFR<30ml/min HCV treatment history: HCV treatment-naive participants, defined as never having received HCV treatment with any approved or investigational drug (including vaccines); OR HCV treatment-experienced, defined as having received previous HCV treatment with any (pegylated) interferon ([Peg]IFN)-based drug regimen (with or without ribavirin [RBV] and not including a direct-acting antiviral agent [DAA]). Last dose in this previous HCV treatment course should have occurred at least 2 months prior to screening No baseline mutation NS5A polymorphism including L31F/I/M/V and Y93H  A patient who having received Daclatasvir or Asunaprevir Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study Evidence of a medical condition contributing to chronic liver disease other than HCV or seropositive for HIV Diagnosed or suspected hepatocellular carcinoma or other malignancies Any history of, or current evidence of, clinical hepatic decompensation (e.g., ascites, encephalopathy or variceal hemorrhage) Received solid organ or bone marrow transplant Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance Significant renal, cardiovascular, pulmonary, or neurological disease and uncontrolled diabetes or hypertension in the opinion of the investigator Known hypersensitivity to study drugs, metabolites, or formulation excipients Who has taken investigational drugs within 2 months
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Lymphoma Hepatitis C Antibodies Drug Therapy Newly diagnosed histologically proven malignant lymphoma 2. Eligible subjects must be positive for anti-HCV Ab 3. Age ≥ 20 years 4. Planned to receive chemotherapy 5. No recent chemotherapy and radiotherapy in the past one year. Pre-enrollment steroids for symptomatic relief are allowed but less than equivalent dose to prednisolone total 140 mg 6. Left expectancy ≥ 3 months 7. Signed informed consent 8. ECOG 0-2  Patients not willing to receive chemotherapy 2. Chronic hepatitis B infection (positive for HBsAg), but those with resolved HBV infection (positive for anti-HBc and negative for HBsAg) are allowed 3. Other major systemic diseases, such as active infection, significant cardiac disease, neurologic deficit or psychiatric disorders, that the investigators consider to be at significant risk 4. Known human immunodeficiency virus (HIV) infection 5. Pregnant or breast-feeding woman
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 21.0-65.0,  Nicotine Dependence Have no known serious medical conditions Are 21-65 years old Smoke an average of at least 10 cigarettes per day Have smoked at least one cumulative year Have an expired air CO reading of at least 10ppm Are able to read and understand English. Potential subjects must agree to use acceptable contraception during their participation in this study. Potential subjects must agree to avoid the following during their participation in this study Participation in any other nicotine-related modification strategy outside of this protocol Use of tobacco products other than cigarettes, including pipe tobacco, cigars, snuff, and chewing tobacco Use of e-cigarettes other than the ones provided during the study Use of experimental (investigational) drugs or devices  Actively seeking treatment for nicotine dependence Uncontrolled high blood pressure (self-report) Coronary heart disease with symptoms (e.g., chest pain) Heart attack in the past year Cardiac rhythm disorder (irregular heart rhythm with symptoms) Chest pain in the last month (unless history indicates a non-cardiac source) Symptomatic heart disorder such as heart failure Advanced liver or kidney disease that requires medication or dialysis, paracentesis Bleeding stomach ulcers in the past 30 days Lung disease that requires oxygen
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hepatitis C has HCV RNA (>= 10,000 IU/mL in peripheral blood) at screening has documented HCV GT3 (with no evidence of non-typeable or mixed GT infection) has compensated cirrhosis of the liver has liver imaging within 6 months of Day 1 with no evidence of hepatocellular carcinoma (HCC) is either HCV TN or TE (i.e., has documented prior virologic failure or intolerance to peg-interferon/ribavirin) is otherwise healthy as determined by medical history, physical examination, electrocardiogram (ECG), and clinical laboratory measurements has compensated cirrhosis of the liver is TN or TE (i.e., documented prior virologic failure or intolerance to peg-interferon/ribavirin) is not of reproductive potential, or agrees to not impregnate a partner or become pregnant for at least 2 weeks prior to the first dose of study drug, and for 7 months after the final dose of study drug (or longer if dictated by local regulations)  has previously received one or more doses of a direct-acting antiviral (DAA) has evidence of decompensated liver disease is coinfected with hepatitis B (hepatitis B surface antigen [HBsAg] positive) has a recent (within 5 years) history of malignancy or is under evaluation for HCC or other suspected malignancy is currently or has participated (within past 30 days) in a study with an investigational compound has clinically-relevant drug or alcohol abuse within the past 12 months of screening is a female and is pregnant or breast-feeding is a male whose female partner is/are pregnant has any of the following organ transplants